Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP increased its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 9.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,448 shares of the company’s stock after purchasing an additional 4,352 shares during the quarter. GSA Capital Partners LLP owned 0.19% of Castle Biosciences worth $1,162,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CSTL. RiverPark Advisors LLC raised its holdings in Castle Biosciences by 362.2% during the first quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after purchasing an additional 2,242 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Castle Biosciences by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,110 shares of the company’s stock worth $67,000 after buying an additional 2,421 shares during the period. Assetmark Inc. increased its holdings in Castle Biosciences by 21.3% in the fourth quarter. Assetmark Inc. now owns 4,736 shares of the company’s stock valued at $102,000 after buying an additional 832 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Castle Biosciences by 943.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,739 shares of the company’s stock worth $124,000 after purchasing an additional 5,189 shares during the last quarter. Finally, WuXi AppTec Co. Ltd. acquired a new stake in Castle Biosciences in the fourth quarter valued at $143,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Stock Performance

NASDAQ:CSTL remained flat at $17.85 on Wednesday. The company’s stock had a trading volume of 99,319 shares, compared to its average volume of 259,443. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.02 and a current ratio of 9.25. Castle Biosciences, Inc. has a 12 month low of $12.07 and a 12 month high of $25.91. The business has a fifty day moving average of $22.79 and a two-hundred day moving average of $21.93. The stock has a market capitalization of $492.84 million, a PE ratio of -15.52 and a beta of 0.93.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. The firm had revenue of $72.97 million during the quarter, compared to analysts’ expectations of $68.34 million. As a group, analysts predict that Castle Biosciences, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird reiterated an “outperform” rating and issued a $34.00 price objective on shares of Castle Biosciences in a research report on Friday, July 5th.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,368 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $24.72, for a total value of $58,536.96. Following the transaction, the insider now owns 62,629 shares in the company, valued at approximately $1,548,188.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Derek J. Maetzold sold 2,368 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $24.72, for a total transaction of $58,536.96. Following the sale, the insider now directly owns 62,629 shares of the company’s stock, valued at approximately $1,548,188.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Bradbury sold 23,323 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $24.64, for a total transaction of $574,678.72. Following the completion of the transaction, the director now owns 9,981 shares in the company, valued at $245,931.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,427 shares of company stock valued at $736,715. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.